Meeder Asset Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Meeder Asset Management’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-103	Closed	-$1K	–	2554
2020 Q1	$1K	Sell	103 -88	-46%	-$1.64K	﹤0.01%	2253
2019 Q4	$5K	Buy	191 +55	+40%	+$1.29K	﹤0.01%	1810
2019 Q3	$3K	Buy	+136	New	+$4.29K	﹤0.01%	1903
2019 Q1	–	Sell	-4,484	Closed	-$87K	–	1902
2018 Q4	$87K	Buy	4,484 +2,674	+148%	+$100K	0.01%	675
2018 Q3	$94K	Buy	1,810 +23	+1%	+$1.25K	0.01%	655
2018 Q2	$77.7K	Buy	+1,787	New	+$76.6K	0.01%	670

Other funds holding GTHX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Meeder Asset Management's GTHX Position: Q2 2020 in Review

Meeder Asset Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2020, closing a stake of 103 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in GTHX in Q2 2018 and held it in 6 quarters. The position peaked at $94K in Q3 2018. 100 funds tracked by Wall St. Rank hold GTHX as of Q2 2020.

Meeder Asset Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Meeder Asset Management sold 103 G1 Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $1K.
Meeder Asset Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
Meeder Asset Management's G1 Therapeutics, Inc. Common Stock position peaked at $94K in Q3 2018.
100 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.